FDA Approves Farxiga Oral Medication To Prevent Progression Of Chronic Kidney Disease

The U.S. Food and Drug Administration approved Farxiga (dapagliflozin) oral tablets to reduce the risk of kidney function decline, kidney failure, cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease who are at risk of disease progression. Farxiga was originally approved in 2014 to improve glycemic control in adults with type 2 diabetes in addition to diet and exercise. The medication was developed by AstraZeneca.

The medication’s efficacy evaluated in a multicenter, double-blind study with 4,304 participants with chronic kidney disease. Of those who received Farxiga, 9.2% later had a 50 . . .